© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Patient Care Editorial Staff
Articles
5 Challenges Physicians Face When Screening for Cognitive Decline
June 19, 2025
Primary care clinicians are generally the first clinical contact for older adults with early signs of dementia. Our survey uncovered 5 primary challenges to being in that role.
Physician Survey Results: Primary Care Knowledge of Screening for Cognitive Decline
June 17, 2025
New survey finds that most PCPs screen for mild cognitive impairment, but time is an issue, guidelines are few, and low levels of confidence persist.
FDA Clears First Plasma-Based Assay to Aid Alzheimer Disease Diagnosis
May 17, 2025
The diagnostic is designed to help clinicians determine the likelihood of cerebral β-amyloid plaque deposition, one of the neuropathologic hallmarks of AD.
ACOG Issues Consensus Guidance to Improve Pain Control During In-Office Gynecologic Procedures
May 16, 2025
Every patient should be offered evidence-based analgesia for pain management for in-office uterine and cervical procedures after shared, trauma-informed decision-making.
ACOG 2025: Menopause and Vasomotor Symptoms Preview
May 16, 2025
A preview of sessions covering menopause and vasomotor symptoms during ACOG 2025 in Minneapolis, MN.
Physician Survey: Assessing Cognitive Decline in Primary Care
May 07, 2025
Primary care clinicians are on the frontline of detecting early cognitive decline. Help us understand your challenges by taking this short survey.
FDA Approves Omlyclo as First Interchangeable Omalizumab Biosimilar
March 10, 2025
Omlyclo is indicated for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and chronic spontaneous urticaria.
Zabalafin Hydrogel Shows Efficacy in Atopic Dermatitis, Including Cases with Bacterial Infection
March 10, 2025
Data on zabalafin hydrogel topical therapy may offer a single, comprehensive approach to manage AD across multiple disease stages.
Ruxolitinib Cream 1.5% Demonstrates Efficacy in Prurigo Nodularis: Phase 3 Findings
March 08, 2025
Data from the TRuE-PN trial program were presented at the 2025 American Academy of Dermatology Annual Meeting in Orlando, offering important insights into potential new therapeutic options for this debilitating condition.